Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon
Leslie Harris
LH
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects*; D004341:Drug Evaluation; D042783:Endothelial Cells / Q000187:drug effects*; D005060:Europe; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013267:Stilbenes / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D008024:Ligands; D013267:Stilbenes; C058728:fosbretabulin